Product Data Sheet



®

Lexatumumab

Cat. No.:	HY-P99299
CAS No.:	845816-02-6
Target:	Apoptosis
Pathway:	Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

Description	Lexatumumab (HGS-ETR 2) is a human agonistic TRAIL receptor 2 (TRAIL-R2, DR5, APO-2) IgG4κ type monoclonal antibody. Lexatumumab induces apoptosis in malignant mesothelioma. Lexatumumab can be used for malignant pleural mesothelioma (MPM) research ^[1] .		
IC ₅₀ & Target	TRAIL-R2 ^[1]		
In Vitro	The combination of <u>Cisplatin</u> (HY-17394) with Lexatumumab synergistically inhibits the cell growth and enhanced apoptotic death ^[1] . Lexatumumab (0-10 μg/ml, 72 h) induces various degrees of cell death in the different melanoma cell lines ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability Assay ^[2]		
	Cell Line:	Melanoma cell lines	
	Concentration:	0.01, 0.1, 1.0 and 10.0 μg/ml	
	Incubation Time:	72 h	
	Result:	Induced various degrees of cell death in the different cell lines.	
In Vivo	Lexatumumab (10 mg/kg, i.v., twice a week) increases antitumor effect in vivo when combined with <u>Dacarbazine</u> (HY-B0078) [2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.		
	Animal Model:	FEMX-1 xenografts mice ^[2]	
	Dosage:	10 mg/kg, 10 mg/kg+Dacarbazine (62.5 mg/kg once a week, i.p. injection)	
	Administration:	i.v., twice a week	
	Result:	Increased antitumor effect in vivo when combined with <u>Dacarbazine</u> (HY-B0078). Induced cleavage of livin into its truncated, proapoptotic form, a compound previously shown to accelerate apoptosis.	

REFERENCES

[1]. Belyanskaya LL, et al. Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin. Mol Cancer. 2007 Oct 22;6:66.

[2]. Engesæter B, et al. Dacarbazine and the agonistic TRAIL receptor-2 antibody lexatumumab induce synergistic anticancer effects in melanoma. PLoS One. 2012;7(9):e45492.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA